Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study.

CONTEXT Endometrial cancer is associated with metabolic disturbances related to its underlying risk factors, including obesity and diabetes. Identifying metabolite biomarkers associated with endometrial cancer may have value for early detection, risk assessment, and understanding etiology. OBJECTIVE The objective of the study was to evaluate the reliable measurement of metabolites in epidemiological studies with nonstandardized blood collection; confirm previously reported correlations of metabolites with body size; and assess differences in metabolite levels between cases and controls. DESIGN This was the Polish Endometrial Cancer Study (2001-2003). SETTING This study was a population-based case-control study. PATIENTS Patients included 250 cases and 250 controls. INTERVENTION The intervention included the measurement of serum metabolite levels of 15 amino acids, 45 acylcarnitines, and nine fatty acids. MAIN OUTCOME MEASURE The main outcome measure was endometrial cancer. RESULTS Body mass index was correlated with levels of valine (r = 0.26, P = 3.4 × 10(-5)), octenoylcarnitine (r = 0.24, P = 1.5 × 10(-4)), palmitic acid (r = 0.26, P = 4.4 × 10(-5)), oleic acid (r = 0.28, P = 9.9 × 10(-6)), and stearic acid (r = 0.26, P = 2.9 × 10(-5)) among controls. Only stearic acid was inversely associated with endometrial cancer case status (quartile 4 vs. quartile 1: odds ratio 0.37, 95% confidence interval 0.20-0.69, P for trend = 1.2 × 10(-4)). Levels of the C5-acylcarnitines, octenoylcarnitine, decatrienoylcarnitine, and linoleic acid were significantly lower in cases than controls (odds ratios ranged from 0.21 to 0.38). CONCLUSIONS These data demonstrate that previously reported variations in metabolomic profiles with body mass index can be replicated in population-based studies with nonfasting blood collection protocols. We also provide preliminary evidence that large differences in metabolite levels exist between cases and controls, independent of body habitus. Our findings warrant assessment of metabolic profiles, including the candidate markers identified herein, in prospectively collected blood samples to define biomarkers and etiological factors related to endometrial cancer.

[1]  E. Tai,et al.  Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men , 2010, Diabetologia.

[2]  F. Di Lisa,et al.  Isovalerylcarnitine is a specific activator of the high calcium requiring calpain forms. , 1990, Biochemical and biophysical research communications.

[3]  J. Chang-Claude,et al.  Serum levels of C‐peptide, IGFBP‐1 and IGFBP‐2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition , 2007, International journal of cancer.

[4]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[5]  C. Welsch,et al.  Relationship between dietary fat and experimental mammary tumorigenesis: a review and critique. , 1992, Cancer research.

[6]  J. Manson,et al.  A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[7]  K. Newton,et al.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. , 2008, American journal of epidemiology.

[8]  Jeremiah Stamler,et al.  Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. , 2010, Journal of clinical epidemiology.

[9]  M. Falchi,et al.  Evaluation of carnitine, acetylcarnitine and isovalerylcarnitine on immune function and apoptosis. , 2005, Drugs under experimental and clinical research.

[10]  B. Horecker,et al.  Isovalerylcarnitine is a specific activator of calpain of human neutrophils. , 1987, Biochemical and biophysical research communications.

[11]  R. Shore,et al.  Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study , 2001, British Journal of Cancer.

[12]  L. Svetkey,et al.  The STEDMAN project: biophysical, biochemical and metabolic effects of a behavioral weight loss intervention during weight loss, maintenance, and regain. , 2009, Omics : a journal of integrative biology.

[13]  C. Friedenreich,et al.  Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  M. Walsh,et al.  Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. , 2006, The American journal of clinical nutrition.

[15]  E. Emken.  Metabolism of dietary stearic acid relative to other fatty acids in human subjects. , 1994, The American journal of clinical nutrition.

[16]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[17]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[18]  P. Knekt,et al.  Serum Fatty Acids and Breast Cancer Incidence , 2003, Nutrition and cancer.

[19]  P. Kris-Etherton,et al.  Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review. , 2010, The American journal of clinical nutrition.

[20]  J. Després,et al.  Abdominal obesity and metabolic syndrome , 2006, Nature.

[21]  F Berrino,et al.  Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer , 2011, British Journal of Cancer.

[22]  M. García-Closas,et al.  Established breast cancer risk factors by clinically important tumour characteristics , 2006, British Journal of Cancer.

[23]  William E. Kraus,et al.  Relationships Between Circulating Metabolic Intermediates and Insulin Action in Overweight to Obese, Inactive Men and Women , 2009, Diabetes Care.

[24]  J. Chang-Claude,et al.  Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2008, Endocrine-related cancer.

[25]  M. García-Closas,et al.  Active and passive cigarette smoking and the risk of endometrial cancer in Poland. , 2010, European journal of cancer.

[26]  I. Wilson,et al.  A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. , 2006, The Analyst.

[27]  M. García-Closas,et al.  Reproductive risk factors for endometrial cancer among Polish women , 2007, British Journal of Cancer.

[28]  Remi Rabasa-Lhoret,et al.  Metabolic and body composition factors in subgroups of obesity: what do we know? , 2004, The Journal of clinical endocrinology and metabolism.

[29]  F. Berrino,et al.  Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer , 2004, International journal of cancer.

[30]  Svati H Shah,et al.  Differential Metabolic Impact of Gastric Bypass Surgery Versus Dietary Intervention in Obese Diabetic Subjects Despite Identical Weight Loss , 2011, Science Translational Medicine.

[31]  E. Riboli,et al.  Biomarkers of dietary fatty acid intake and the risk of breast cancer: A meta‐analysis , 2004, International journal of cancer.

[32]  R. Hoover,et al.  Dietary associations in a case-control study of endometrial cancer , 1993, Cancer Causes & Control.

[33]  I. Wilson,et al.  Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. , 2007, Journal of proteome research.

[34]  S. Hankinson,et al.  Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. , 2011, American journal of obstetrics and gynecology.

[35]  R. Mensink,et al.  Effects of fats and fatty acids on blood lipids in humans: an overview. , 1994, The American journal of clinical nutrition.